MRTX1133 KRAS CAN BE FUN FOR ANYONE

The identification of KRASG12C inhibitors has reignited fascination in targeting RAS proteins. This work describes the discovery from the KRASG12D-unique inhibitor MRTX1133 and demonstrates the feasibility of potently and selectively focusing on this oncogenic variant.And clinical trials of mixture therapy with KRAS G12C inhibitors and immune check